PRGO - BioLineRx: With A Lot Of Cash In Hand And Undervalued
At Phase 3 of development, expecting to have $55 million in cash after the sale of warrants and with very little debt, BioLineRx (BLRX) is interesting. In addition, the company trades with an enterprise value of only $12 million, which seems very small. Other competitors at a similar stage of development have an enterprise value of more than $264 million. On top of it, the company is expected to release new data in the next 12 months, which could make the share price increase. With all this in mind, institutional investors should have a look